Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.71 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PAK4 | O96013 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29787379 | 1.00 | CRBN (0.71) | CRBNCHEK1AURKADAPK3JAK2 | |
| SCHEMBL22612095 | 0.83 | CRBN (1.00) | CRBNCHEK1AURKADAPK3JAK2 | |
| SCHEMBL36363978 | 0.83 | CRBN (1.00) | CRBNCHEK1AURKADAPK3JAK2 | |
| SCHEMBL6411615 | 0.77 | CRBN (0.46) | CRBNCDK5SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL8470423 | 0.75 | CRBN (0.41) | CRBNALDH1A1KDM4E | |
| SCHEMBL9823405 | 0.73 | NPC1 (0.45) | CRBNPIM1PTK2SMN1; SMN2ALDH1A1 | |
| SCHEMBL30702779 | 0.73 | CRBN (0.63) | CRBNCHEK1AURKADAPK3JAK2 | |
| SCHEMBL2198674 | 0.73 | CRBN (0.63) | CRBNCHEK1AURKADAPK3JAK2 | |
| SCHEMBL29048963 | 0.72 | CRBN (0.54) | CRBNALOX5SMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL746783 | 0.71 | CRBN (0.66) | CRBNGSK3AGSK3BALOX5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD (CN) | 2024-09-12 | — | — | US | disclosed |
| US-11724999-B2 | Inhibitors of RAS-effector protein interactions | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-11724999-B2 | Inhibitors of RAS-effector protein interactions | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20210047305-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| EP-3743414-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | Oxford University Innovation Limited (GB) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019145719-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019145719-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-08-01 | — | — | WO | disclosed |
| US-8652452-B2 | 2,4-disubstituted pyridines as perfuming ingredients | FIRMENICH SA (CH) | 2014-02-18 | — | — | US | disclosed |
| EP-2552395-B1 | 2,4-disubstituted pyridines as perfuming ingredients | FIRMENICH & CIE (CH) | 2013-11-13 | — | — | EP | disclosed |
| EP-2552395-A1 | 2,4-DISUBSTITUTED PYRIDINES AS PERFUMING INGREDIENTS | Firmenich S.A. (CH) | 2013-02-06 | — | — | EP | disclosed |
| US-20130004447-A1 | 2,4-DISUBSTITUTED PYRIDINES AS PERFUMING INGREDIENTS | FIRMENICH SA (CH) | 2013-01-03 | — | — | US | disclosed |
| CN-102802600-A | 2, 4-disubstituted pyridines as perfuming ingredients | FIRMENICH & CIE | 2012-11-28 | — | — | CN | disclosed |
| WO-2011121469-A1 | 2,4-DISUBSTITUTED PYRIDINES AS PERFUMING INGREDIENTS | FIRMENICH SA (CH) | 2011-10-06 | — | — | WO | disclosed |
| JP-2003081971-A | 5-PYRIDYLMETHYLHYDANTOIN AND N-CARBAMOYL-3-(PYRIDYL) ALANINE | K I CHEMICAL INDUSTRY CO LTD | 2003-03-19 | — | — | JP | disclosed |
| EP-0816342-B1 | Process for producing 1-substituted-hydantoins | SUMITOMO CHEMICAL CO (JP) | 2002-02-27 | — | — | EP | disclosed |
| US-5883260-A | Process for producing 1-substituted-hydantoins | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-03-16 | — | — | US | disclosed |
| EP-0816342-A2 | Process for producing 1-substituted-hydantoins | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-01-07 | — | — | EP | disclosed |
| EP-0200299-B1 | PYRIDINYLIMIDAZOLIDINONE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1990-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130004447-A1 | 2,4-DISUBSTITUTED PYRIDINES AS PERFUMING INGREDIENTS | P2RX5, P2RX4, C5 | CRBN 1469/4885CHEK1 1181/4885AURKA 966/4885 |
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | ADAMTS5, ADAMTS4, ADAMTS1 | CRBN 1432/4885CHEK1 4447/4885AURKA 4641/4885 |
| US-20210047305-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | KRAS, NRAS, HRAS | CRBN 1604/4885CHEK1 644/4885AURKA 1611/4885 |
| US-11724999-B2 | Inhibitors of RAS-effector protein interactions | KRAS, NRAS, HRAS | CRBN 1604/4885CHEK1 644/4885AURKA 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.